FDA Approves Monkeypox Vaccine, says it May Cause Death in the Vaccinated AND People They Come in Contact With
On August 29 the FDA approved for use in the U.S. a vaccine [ACAM2000] for Monkeypox. While the injection is actually a Smallpox vaccine initially approved in 2007, this new approval allows the shot to be injected into those at ‘high risk’ for the Monkeypox disease, such as those in the LGBTQIAAP2S+ community. It carries with it serious side effect risks, including death to those who have contact with the vaccinated.
“…the FDA approved a new indication for ACAM2000 [the vaccine], to include the prevention of mpox disease in individuals determined to be at high risk for mpox infection. ACAM2000 has been approved since 2007 for the prevention of smallpox disease in individuals determined to be at high risk for smallpox infection. ACAM2000 is a live replicating vaccinia virus vaccine,” an FDA press release said on August 30.
The medication guide found on the FDA’s website for the vaccine lists numerous serious side effects on page 1.
While many of the side effects are similar to that of the Covid exotic technology injections, perhaps the most alarming sentence of the medication guide is that these serious side effects can afflict those who come into close contact with a Monkeypox-vaccinated individual.
“[The vaccine] can cause serious complications in vaccinated individuals and in their close contacts to whom the vaccine virus has spread,” the medication guide said on page 1.
The package insert for the Monkeypox vaccine also includes the proviso of serious side effects for those shed upon by the vaccinated.
Importantly, that piece of literature goes so far as to state that the same specific serious side effects can be spread via shedding,
“[The vaccine] is a live vaccinia virus that can be transmitted to persons who have close contact with the vaccinee and the risks in contacts are the same as those stated for vaccinees,” the package insert said on page 1 in the ‘Warnings and Precautions’ section.
While that section only mentioned fetal death as a side effect, the initial ‘Serious Complications’ section of the package insert, found on page 1, does mention death as a side effect of the Monkeypox vaccine, implying that those who have contact with a Monkeypox-vaccinated individual may die.
ACAM2000 is a vaccine used to prevent smallpox and mpox disease.
— Toast on the Side (@toastontheside) September 17, 2024
Read from the FDA site:https://t.co/ZVxvBqVyXq
This is disaster waiting to happen! pic.twitter.com/0RlFN2pttZ
An unusual direction is given in section 2.4 ‘Vaccine Administration’ on page 4 of the package insert. Cleaning the vaccination site (the upper arm) with an alcohol wipe is advised against, unless the arm is dirty. This likely sounds bizarre by anyone who’s gotten vaccines before, however it’s stated that the residual alcohol can deactivate the live viruses of the injection.
“No skin preparation should be performed unless the skin at the intended site of vaccination is obviously dirty, in which case an alcohol swab(s) may be used to clean the area. If alcohol is used, the skin must be allowed to dry thoroughly to prevent inactivation of the live vaccine virus by the alcohol,” the package insert said in the ‘Vaccine Administration’ section on page 4.
Post-vaccine care also differs from most other vaccines, as a usual bandaid over the injection site is not called for, but rather gauze.
“Ensure each vaccine recipient has the FDA-approved Medication Guide, which includes instructions for care of the vaccination site. Cover vaccination site with gauze and secure it loosely with first aid adhesive tape. The gauze provides a barrier to protect against spread of the vaccinia virus. If the vaccinee is involved in direct patient care, the gauze may be covered with a semipermeable (semi-occlusive) dressing as an additional barrier. A semipermeable dressing is one that allows for the passage of air but does not allow for the passage of fluids. Do not use a bandage that blocks air from the vaccination site. This may cause the skin at the vaccination site to soften and wear away,” the package insert said in the ‘Care of the Vaccination Site’ section on page 5.
These differentiating factors with vaccine administration stem from the fact that the Monkeypox vaccine is also administered in a different way than most other vaccines.
“[The vaccine] is given ‘percutaneously.’ Your healthcare provider will make 15 pokes in the skin of
your upper arm with a two-prong needle holding a small drop of [the vaccine]. The pokes are not
deep but will cause a drop of blood to form. Where the 15 pokes are made is called the
vaccination site,” the medication guide said on page 2.
Suzanne Burdick, Ph.D. reported in The Defender on Tuesday that the Monkeypox vaccine manufacturer is tied to biochemical warfare threats.
“ACAM2000 — made by Emergent BioSolutions, a company specializing in vaccines for biochemical warfare threats such as anthrax and smallpox,” Suzanne Burdick, Ph.D. reported in The Defender on Tuesday.
The Monkeypox vaccine, like the smallpox vaccine, is considered ‘effective’ when development of a major cutaneous reaction (characterized by a pustule) at the site of inoculation occurs.
“In an individual vaccinated for the first time (primary vaccination; vaccinia-naïve), the expected response to vaccination is the development of a major cutaneous reaction (characterized by a pustule) at the site of inoculation. The lesion evolves gradually, with appearance of a papule at the site of vaccination after 2-5 days. The papule becomes vesicular surrounded by a red areola, then pustular, and reaches its maximum size at 8-10 days after vaccination; the pustule dries and forms a scab (See Figure 1). In primary vaccinees, scab separation and re-epithelialization occurs 3-6 weeks after vaccination, leaving a pitted scar. Formation of a major cutaneous reaction by day 6-11 is evidence of a successful ‘take’ and acquisition of protective immunity. An equivocal reaction is any reaction that is not a major reaction,” the package insert said in section ‘Interpreting Vaccination Response’ on page 5 and 6.
Images of the pustule are included on pages 7 and 8 of the package insert.
Dr. Peter McCullough wrote on his Substack that Monkeypox is a disease that primarily affects the butts of gay men.
“President Biden and HHS Secretary Becerra declared a US Monkeypox Public Health Emergency in 2022 and let the declaration expire early in 2023. The crisis conjured up little fear for the average American as it was learned that the infection was largely a pustular rash that occurred with intense sexual contact among gay/bisexual men with the skin blisters around the anus and buttocks or mouth,” McCullough said on his Substack on August 18. “A report by Kannan et al, indicated that what happened in 2022 almost certainly occurred because of a gain-of-function mutation in one or more genes within the Monkeypox virus.”
Gain-of-Function Mutation Discovered in Monkeypox Virus - May Explain Clade II Human Outbreak in 2022, WHO Declares Emergency in 2024
— McCullough Foundation (@McCulloughFund) August 18, 2024
A report by Kannan et al, indicated that what happened in 2022 almost certainly occurred because of a gain-of-function mutation in one or more… pic.twitter.com/QxUeD49Kav
The gay-butt Monkeypox hysteria has led some on social media to produce satirical memes.
The covidiots are already starting to wear their monkeypox protection ....#monkeypox pic.twitter.com/iAhTTTeiM5
— Filippo Maria O di B (@filippomaria60) August 16, 2024
The name Monkeypox has undergone a social justice rebranding to ‘Mpox’ in order to omit the word ‘Monkey’ as that was said to offend the black people.
